Targeting allosteric binding sites represents a powerful mechanism for selectively modulating receptor function. The advent of functional assays as the screening method of choice is leading to an increase in the number of allosteric modulators identified. These include positive allosteric modulators that can increase the affinity of the orthosteric agonist and potentiate the evoked response. A common method for screening for positive allosteric modulators is to examine a concentration-response (C/R) curve to the putative modulator in the presence of a single, low concentration of agonist. The study reported here has used data simulations for positive allosteric modulators according to the allosteric ternary complex model to generate modulator C/R curves. The results are then compared to the mechanistic parameters used to simulate the data. It is clear from the simulations that the potency of a positive modulator C/R curve in a screening assay is the product of both its affinity and positive cooperativity. However, it is often difficult to tell which parameter dominates the response; not knowing the actual affinity or cooperativity of a ligand may have consequences for receptor selectivity. Further modeling demonstrates that the use and choice of single agonist concentration, as well as changes in the agonist curve Hill slope, can have significant effects on the modulator C/R curve. Finally, the quantitative relationship between modulator C/R curves and the allosteric ternary complex model is explored. These simulations emphasize the importance of careful interpretation of screening data and of conducting full mechanism of action studies for positive allosteric modulators. (Journal of Biomolecular Screening 2007:668-676) 
INTRODUCTION
T HE PREFERENCE FOR FUNCTIONAL ASSAYS as the highthroughput drug discovery screen of choice has led to an increasing array of different receptor ligands being identified. 1 Prominent among these are allosteric ligands, which bind to sites on receptors (ligand-gated ion channels, G-proteincoupled receptors, tyrosine kinase receptors, etc.) that are topographically distinct from the orthosteric binding site (the site for the endogenous ligand for the receptor). Upon binding, they are able to alter the conformation of the orthosteric site and modify orthosteric agonist affinity. Allosteric modulators possess a number of advantages as potential drugs, including the prospect of enhanced selectivity, an inherent saturability to their effect, and the ability to modulate subtly receptor function while maintaining the temporal and spatial resolution of receptor signaling. 1, 2 Although it is increasingly being recognized that allosteric ligands can have effects on orthosteric agonist efficacy as well as affinity, most allosteric modulators identified to date typically affect only the latter. The actions of such compounds can be described mechanistically by the allosteric ternary complex model (ATCM; Fig. 1 ). 2, 3 Allosteric modulators that affect orthosteric agonist binding affinity are typically detected in functional assays; the effects of the modulators would be manifested as a change in agonist potency (either a rightward or leftward parallel shift in the agonist concentration-response [C/R] curve) that would progressively approach a limit, with the maximal shift being governed by the cooperativity factor, α ( Fig. 1) . 2, 3 The cooperativity represents the strength and direction of interaction between the orthosteric and allosteric ligands; values of α > 1 represent positive cooperativity, whereas values of α < 1 represent negative cooperativity. If α = 1, then the cooperativity is neutral. Unlike for orthosteric ligand-receptor interactions, the cooperativity between an allosteric and orthosteric ligand depends on the choice of orthosteric ligand-this is known as probe dependency. It is for this reason that, when screening for allosteric modulators as drugs, the endogenous ligand for the target in question should always be used as the orthosteric agonist.
If, when testing for the effects of allosteric modulators, there is no significant effect noted on the maximum or minimum asymptotes of the agonist C/R curve, then this is often taken as presumptive evidence of a simple ATCM mechanism. However, it must be noted that in systems of high receptor reserve, leftward shifts of an agonist C/R curve could reflect an increase in agonist efficacy rather than affinity. This would result in an increase in potency, as the maximal agonist response would already reflect the maximal response of the assay system. Despite this caveat, the ATCM model can be readily applied to the functional data to obtain estimates of modulator affinity (pK B ) and cooperativity (α). 4 However, to obtain such data requires full C/R curves to the chosen agonist in the presence of typically 3 to 6 concentrations of the putative modulator. This is clearly a large amount of work and is not always suited to high-throughput screening (HTS). Of course, this is an operational decision; with the advances in liquid handling and HTS platforms, it may well be possible (and desirable) to perform high-throughput mechanism of action studies. However, it has now become commonplace to screen for positive allosteric modulators (which are expected to shift the agonist C/R curve to the left) by testing a single, low concentration of agonist (often an EC 20 ) in the presence of varying concentrations of modulator ( Fig. 2) . 5 This paradigm generates a "modulator C/R curve," which can be analyzed using a simple logistic 4-parameter fit (Fig. 2) ; 6 comparisons between different modulators are then based on the fitted pEC 50 values and maximal asymptotes of such curves.
However, the action of a positive allosteric modulator is defined by 2 parameters: a measure of affinity (pK B ) and cooperativity with respect to the orthosteric agonist (α). It is currently unclear how potency and maximal response data from modulator C/R curves relate to affinity and cooperativity for a modulator and hence how such data should be interpreted. This relationship is key as it clearly affects the lead optimization process in terms of selectivity (and cooperativity if this is a key structure-activity relationship [SAR] parameter).
The aim of this study is to investigate the relationship between the parameters described in the ATCM and those derived from positive modulator C/R curves. Using the "simulate and generate" function of GraphPad Prism 4, which allows the user to simulate data sets for both standard and user-defined nonlinear regression equations, 6 simulations of agonist C/R curves in the presence of varying concentrations of a positive allosteric modulator are generated according to the ATCM. [2] [3] [4] The predicted response to an EC 20 of agonist in the presence of a positive allosteric modulator can then be determined and plotted against the modulator concentration, yielding a modulator C/R curve.
It is then possible to determine how varying a number of factors, including the effective concentration of agonist used, as well as affinity and cooperativity of the modulator and the agonist curve Hill slope, affects the modulator C/R curve output. The modeling shows that varying the effective concentration of agonist used and the Hill slope of the agonist curve has significant but modest effects on modulator C/R curves. However, variations in affinity (pK B ) or cooperativity (α) can have much larger effects on modulator C/R curves, which could have significant implications for modulator SAR screening.
Finally, the quantitative relationship between modulator C/R curve parameters and the ATCM is explored to provide a simple method for directly analyzing modulator C/R curves according to the ATCM.
METHODS
C/R curve data were modeled using the "simulate and generate" function of GraphPad Prism 4. 6 Model C/R data for an agonist in the presence of varying concentrations of a positive allosteric modulator were generated according to the following equation (1) , which is based on a simple allosteric ternary complex model of ligand-receptor interaction: [2] [3] [4] 
FIG. 1.
Simple allosteric ternary complex model (ATCM). R denotes the receptor, A and B denote the orthosteric and allosteric ligand, respectively, and K A and K B denote the equilibrium dissociation constants of AR and BR, respectively. The symbol α denotes the cooperativity factor and is a quantitative measure of the maximal, reciprocal alteration of affinity of A and B for their respective binding sites when both ligands bind simultaneously to form the ternary complex, ARB.
(1)
where E max represents the maximal asymptote of the curves, Basal represents the lowest asymptote (basal response) of the curves, logEC 50 represents the logarithm of the agonist EC 50 in the absence of antagonist, n H represents the Hill slope of the agonist curve, [A] represents the concentration of the agonist, [B] denotes the concentration of allosteric ligand, K B denotes its equilibrium dissociation constant for binding to the allosteric site on the receptor (pK B represents the negative logarithm of K B ), and α denotes the cooperativity factor, which is a thermodynamic measure of the strength of allosteric interaction between the orthosteric and allosteric sites. Values of α > 1 (log α > 0) denote positive cooperativity (positive allosteric modulation). When simulating curve fits, GraphPad Prism can be configured to provide between 150 and 300 theoretical data points for each curve modeled. This is done over a range of agonist concentrations chosen by the user. This utility allows the predicted assay response to an EC 20 (or EC 10 , EC 30 , etc.) of agonist in the presence of varying concentrations of positive allosteric modulator to be determined ( Fig. 2) . Using these data points, theoretical C/R curves of assay response against allosteric modulator concentration were constructed. These curves represent simulations of the data that would typically be produced by a primary screening assay for positive allosteric modulators. These data were fitted according to the 4-parameter logistic fit (equation (2)): (2) where E max represents the maximal asymptote of the curve, Basal represents the lowest asymptote (basal response) of the curves, logEC 50 represents the logarithm of the agonist EC 50 , and n H represents the Hill slope of the agonist curve.
Using the protocol described above, the following parameters were investigated:
1. The effect of varying cooperativity (α) values on the modulator C/R curve potency and maximal effect 2. The effect that the choice of single agonist concentration has on the modulator C/R curve potency and maximal effect 3. The effect of agonist curve Hill slope on the modulator C/R curve potency For these scenarios, families of curves were generated by varying parameters from equation (1), as described in Table 1 .
RESULTS

Effect of varying positive cooperativity values (α α ) on the modulator C/R curve
The activity of a positive allosteric modulator at a receptor is dependent on 2 properties-namely, a measure of affinity (pK B ), which is intrinsic to the molecule, and cooperativity (α), which is a property unique to the allosteric ligand-orthosteric ligand pair. However, it is currently unclear how these properties relate to potency and maximal response estimates derived from modulator C/R curves. As such, the effects of varying the cooperativity values on the resultant modulator C/R curves for a positive allosteric modulator with a fixed affinity (pK B = 6) were modeled.
As shown in Figure 2 , predicted modulator C/R curves were constructed from model data sets according to equation (1) . Estimates of potency and maximal response could then be related back to original parameters used to construct the data set. Graphs of the modeled data are shown in Figure 3 ; the effect of varying the cooperativity value on the potency and maximal response of the modulator C/R curves is shown in Table 2 .
It can be seen that at low degrees of positive cooperativity (log α = 0.25-0.5), the pEC 50 estimate is a reasonably close approximation of the affinity (pK B ). However, as the degree of positive cooperativity becomes stronger (log α = 1.0-3.0), the maximum response of the modulator C/R curves reaches a plateau, and pEC 50 values subsequently increase linearly with the logarithm of cooperativity ( Fig. 4) , with no effect on Hill slope. A modulator such as example "F" (Fig. 3 ) may yield a high pEC 50 (7.8) despite much lower affinity (pK B = 6).
This can be readily accounted for in terms of the ATCM. By analogy to the relationship between the ATCM parameters and radioligand binding curves, the EC 50 of the modulator C/R curve (EC 50mod ) is defined by equation (3) (all other parameters as defined for equation (1)):
(3)
As α approaches 1 (log α → 0), the EC 50mod approaches the K B . When α approaches large values, the EC 50mod shifts infinitely to the left, as shown in Figure 4 .
For a modulator C/R curve that reaches a maximal response (e.g., 100% in Fig. 3) , it is impossible to determine whether the potency results from low affinity and high cooperativity (cooperativity dominant) or vice versa (affinity dominant-although if the cooperativity were very low, the maximal asymptote would not reach 100%; e.g., example "B" in Fig. 3) . In many respects, this is similar to agonist potency-a readout that is dependent on both agonist affinity and efficacy. It is impossible to determine from a single agonist C/R curve whether an agonist is efficacy or affinity dominant. 7 Although it is possible for allosteric ligands to display absolute subtype selectivity, whereby receptor selective function is derived from cooperativity rather than affinity, 4 in reality, this is unlikely to always be the case. Therefore, not knowing the affinity and cooperativity of an allosteric ligand has many implications for ligand selectivity and SAR (if cooperativity is a key SAR parameter) and underlies the importance of conducting full mechanism of action studies on lead compounds.
It must be noted that this analysis is not predictive for positive modulators that can affect orthosteric agonist efficacy as well as affinity. Modulation of both affinity and efficacy would lead to leftward shifts in the agonist C/R curve as well as changes in the maximal response evoked, as has been mechanistically described in the allosteric 2-state model by Hall. 8 These effects would be translated into the modulator C/R curves and could potentially result in maximal asymptotes greater than or less than the E max for the orthosteric agonist that may confound the predictions contained herein. Again, full mechanism of actions studies would help to reveal the effects of a modulator on orthosteric agonist efficacy.
Effect of choice of single agonist concentration on the modulator C/R curve
When screening for positive allosteric modulators using modulator C/R curves, it is common to use a single, low concentration of agonist, usually an EC 20 . However, different researchers may choose to use different effective agonist concentrations (e.g., an EC 10 or EC 30 ). Even for a "fixed" concentration, such as an EC 20 , inherent biological variation (both inter-and intraassay) will mean that in a given assay, such a fixed agonist concentration may represent an effective concentration slightly higher or lower than the true EC 20 . The effects on the resultant modulator C/R curves of using a EC 10 , EC 20 , and EC 30 of agonist were investigated for theoretical positive allosteric modulators with log α values of 1.0, 1.5, 2.0, and 3.0, all with a fixed pK B = 6 ( Fig. 5; Table 3 ). As observed in the previous section, the potencies of the modulator C/R curve increase with increasing degrees of positive cooperativity. However, use of either a lower (EC 10 ) or higher (EC 30 ) single agonist concentration has a significant effect on the potency of the modulator C/R curve generated compared to that produced when using an EC 20 ( Fig. 5; Table 3 ). Use of a lower concentration of agonist (EC 10 ) yields a significantly lower modulator C/R curve potency, whereas using a higher agonist concentration (EC 30 ) yields a significantly higher potency ( Fig. 5; Table 3 ).
Reducing the fixed agonist concentration from an EC 20 to an EC 10 has a more marked effect on the resultant modulator C/R curve than increasing the concentration to an EC 30 . However, the effect of either change becomes more pronounced as the degree of positive cooperativity is increased and the maximum asymptotes of the 3 modulator C/R curves converge ( Fig. 5 ; Table 3 ). As expected, changes in the single agonist concentration used had no effect on the modulator C/R curve Hill slope. These results suggest that very small variations in the agonist concentration used can have significant effects on the resulting modulator C/R curve.
Effect of agonist curve Hill slope on the modulator C/R curve
Agonist C/R curves can appear steep in screening assays for a number of reasons. Agonist binding to a receptor can be subject to positive homo-cooperativity; this can result in C/R curves with Hill slopes greater than unity. Furthermore, commonly used HTS assays for positive allosteric modulators include measurement of intracellular calcium mobilization using platforms such as the fluorometric imaging plate reader (FLIPR). 9, 10 The relatively downstream measure of calcium mobilization is often subject to a large degree of signal amplification 7 and, as such, the Hill slopes of agonist C/R curves can be significantly greater than unity.
Given these possibilities, the final simulation examined the effect of agonist C/R curve Hill slope on the modulator C/R curve potency and maximal response for a positive allosteric modulator of fixed affinity (pK B = 6) and cooperativity (log α = 1). As shown in Figure 6 and Table 4 , increasing the agonist C/R curve Hill slope results in significant increases in the potency, maximal response, and Hill slope for the resulting modulator C/R curve. The main consequence of an increase in agonist C/R curve Hill slope is that the maximal asymptote of the modulator C/R curve reaches 100% at lower degrees of positive cooperativity than when the agonist C/R curve Hill slope is equal to 1.
Analyzing modulator C/R curves according to the ATCM
The simulations described above indicate that different combinations of parameters can yield similar modulator C/R curvesit is difficult to determine whether a positive allosteric modulator is affinity or cooperativity dependent. However, it would be advantageous to directly analyze modulator C/R curves to obtain the affinity and cooperativity. Clearly, it is not possible to obtain these data from the modulator C/R curve alone. However, by simultaneous analysis of both modulator and agonist C/R curves, it is possible to use equation (1) An example of the analysis of a modulator C/R curve is shown in Figure 7 . Both the agonist and modulator C/R curves (Fig. 7A) have been generated according to equation (1), where pK B = 6, log α = 1.5, Hill slope = 1, Basal = 0, E max = 100, the effective agonist concentration was an EC 20 (300 nM), and [B] ranges from 30 nM to 3 µM.
The combined data set was then analyzed according to the recast ATCM equation (Fig. 7B) , where log [B] is set as the independent variable on the x-axis. Using the global shared analysis feature of GraphPad Prism 4, 6 the values of logEC 50 , Basal, E max , log K B , log α, and Hill slope are shared across both data sets, whereas the orthosteric agonist concentration, [fixed agonist], is set at 300 nM. The results of the analysis are shown in Figure 7C . Note that the values of logEC 50 , Basal, E max , and Hill slope refer to the agonist C/R curve rather than the modulator curve. The resultant estimate of log K B is exactly correct at -6.00, and the estimate of log α of 1.42 is very close to the real value of 1.50. These data suggest that it is possible to derive the ATCM parameters directly from analysis of a modulator C/R curve and may allow for higher throughput mechanism of action studies.
DISCUSSION
These data simulations have studied the use of positive allosteric modulator C/R curves as a screening paradigm. This paradigm has the advantage of reducing the workload required to screen a single compound and provides an easy method for screening positive allosteric modulators. However, as has been demonstrated in the modeling, the output from such screens fails to delineate the 2 parameters of a positive allosteric modulator, affinity and cooperativity. Apart from situations where the modulator C/R curve fails to reach the 100% level, any given modulator C/R curve potency could result from differing combinations of affinity and cooperativity. This has implications for the receptor selectivity of a compound and hence any lead optimization effort centered on discovering selective allosteric modulators. It further highlights the requirement for full mechanism of action studies on advanced compounds. Of course, it is possible that an allosteric modulator that lacks selective affinity for a given receptor may exhibit neutral cooperativity with respect to all other receptors while maintaining positive (or negative) cooperativity with the receptor of interest. This is termed absolute subtype selectivity. 4 However, in reality, this is unlikely to be the case, and knowing the affinity of a compound for the target receptor is a key piece of information. The interesting caveat to these findings is for positive allosteric modulators whose modulator C/R curves reach a maximal asymptote that is significantly lower than 100% of the agonist response. For these compounds, the model predicts that the modulator cooperativity must be low (typically, log α ≤ 1.5 if the agonist Hill slope ≈ 1) and that the pEC 50 value generated is typically no more than 1 log unit greater than the affinity.
Further modeling has also investigated the effect of varying either the single agonist concentration used to generate the modulator C/R curve or the agonist curve Hill slope. The choice of the single concentration of agonist used significantly affects the modulator C/R curve potency, an effect that is more marked for lower effective agonist concentrations. Therefore, using a very low single agonist concentration (an EC 10 or below) will result in low-potency modulator C/R curves (according to equation (3), the EC 50 of the modulator C/R curve approaches the K B value of the modulator as the single agonist concentration used approaches 0). This may be problematic when studying low-affinity modulators. However, using a higher single agonist concentration (greater than an EC 30 ) means that the maximal asymptote of modulator C/R curves will reach 100% at lower values of modulator affinity and/or cooperativity. Clearly, the choice of single agonist concentration represents a balance; the most common choice for screening appears to be an EC 20 .
To maintain consistency, the findings above suggest that for assays run to identify positive modulators (assuming that intraassay variability is lower than interassay variability), the effective agonist concentration chosen should be determined on the day of assay prior to running the modulator C/R assay to ensure the highest level of accuracy.
Agonist curve Hill slope also has a significant effect on modulator C/R curve potency and maximal response. As the agonist curve Hill slope becomes steeper, a common phenomenon in some screening assays, the modulator C/R curve potency and maximal response increase. These changes are small (less than 0.5 log unit shift in pEC 50 and small increases in E max ) for Hill slopes up to 2.5. However, this exacerbates the problems observed in the first model, whereby for modulator C/R curves whose maximal response reaches 100%, it is impossible to determine whether the pEC 50 results primarily from modulator affinity or cooperativity. Because the maximal response increases with increasing agonist curve Hill slope, modulators will fall into this bracket at lower degrees of positive cooperativity.
Finally, the ATCM has been adapted to enable direct analysis of modulator C/R curves to yield estimates of affinity and cooperativity. This is achieved by concomitant analysis of modulator C/R curves and the orthosteric agonist C/R curve ( Fig. 7; A. Christopoulos, personal communication, 2007) . This allows the determination of modulator affinity and cooperativity parameters in a high-throughput format.
However, this method relies on high-quality data with little variability, especially with regard to the modulator C/R curve. The estimate of cooperativity (log α) relies on robust determination of the maximal asymptote of the modulator C/R curve. Bell-shaped C/R curves, or curves whose maximal asymptotes approach that of the agonist C/R curve, may result in estimates of log α with wide error and, in turn, yield inaccurate estimates of pK B . As a result, this methodology does not account for positive allosteric modulators that enhance orthosteric agonist efficacy or display intrinsic agonist activity. However, it does provide an extremely useful method for determining ATCM parameters in a high-throughput format, which may aid SAR campaigns.
These simulations have recognized the usefulness of modulator C/R curves as a screening paradigm, but they highlight that considerable care should be taken in interpreting such data, especially when dealing with apparently potent positive allosteric modulators. The simulations demonstrate that highly potent modulators can be either affinity or cooperativity dominant and that it is impossible to determine which is the case using single modulator C/R curves. The concept of "affinity-dominant" versus "cooperativity-dominant" positive allosteric modulators poses a number of questions with regard to receptor selectivity; therefore, identifying these individual parameters is key to a full appreciation of the positive modulator-receptor interaction. This can be achieved through full mechanism of action studies. Alternatively, this study has also presented a method by which modulator C/R curves can be analyzed according to the ATCM. This method should effectively enable limited mechanism of action studies to be performed in a high-throughput manner. It is hoped that having such mechanistic data available early in the screening campaign will lead to greater understanding of the SAR and behavior of positive allosteric modulators.
